Your browser is no longer supported. Please, upgrade your browser.
KemPharm, Inc.
Index- P/E- EPS (ttm)-4.03 Insider Own10.80% Shs Outstand28.49M Perf Week29.15%
Market Cap408.63M Forward P/E292.40 EPS next Y0.05 Insider Trans0.34% Shs Float25.46M Perf Month65.95%
Income-54.70M PEG- EPS next Q0.23 Inst Own16.00% Short Float13.42% Perf Quarter55.70%
Sales23.30M P/S17.54 EPS this Y75.80% Inst Trans- Short Ratio2.06 Perf Half Y1.95%
Book/sh4.40 P/B3.32 EPS next Y117.90% ROA-174.90% Target Price19.00 Perf Year383.47%
Cash/sh2.72 P/C5.38 EPS next 5Y- ROE204.00% 52W Range2.90 - 22.08 Perf YTD30.54%
Dividend- P/FCF- EPS past 5Y51.40% ROI-242.40% 52W High-33.79% Beta3.30
Dividend %- Quick Ratio20.70 Sales past 5Y- Gross Margin- 52W Low404.83% ATR0.75
Employees22 Current Ratio20.70 Sales Q/Q476.20% Oper. Margin-50.50% RSI (14)85.64 Volatility9.17% 6.24%
OptionableYes Debt/Eq0.01 EPS Q/Q-30.20% Profit Margin- Rel Volume1.39 Prev Close13.35
ShortableYes LT Debt/Eq0.00 EarningsMay 13 AMC Payout- Avg Volume1.66M Price14.62
Recom2.50 SMA2038.85% SMA5049.91% SMA20040.06% Volume2,301,089 Change9.51%
Mar-04-21Downgrade H.C. Wainwright Buy → Neutral $24 → $12
Jan-25-21Initiated ROTH Capital Buy $28
Jun-09-21 07:30AM  
Jun-03-21 07:30AM  
May-26-21 07:30AM  
May-13-21 04:05PM  
May-07-21 07:30AM  
May-06-21 04:30PM  
Apr-21-21 04:45PM  
Apr-09-21 08:08AM  
Mar-17-21 08:30AM  
Mar-11-21 04:25PM  
Mar-09-21 07:30AM  
Mar-05-21 08:15PM  
Mar-04-21 04:41PM  
Mar-03-21 01:00PM  
Mar-02-21 11:31PM  
Feb-28-21 10:54AM  
Feb-27-21 11:58AM  
Feb-05-21 08:30PM  
Jan-27-21 08:30AM  
Jan-14-21 07:30AM  
Jan-13-21 07:30AM  
Jan-08-21 08:30AM  
Dec-23-20 06:11PM  
Dec-22-20 07:30AM  
Dec-02-20 07:30AM  
Nov-30-20 07:30AM  
Nov-23-20 04:30PM  
Nov-18-20 08:30AM  
Oct-29-20 04:05PM  
Oct-22-20 07:30AM  
Aug-14-20 07:30AM  
Aug-12-20 04:05PM  
Jun-21-20 10:06PM  
May-04-20 08:00AM  
KemPharm, Inc., a specialty pharmaceutical company, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company utilizes its Ligand Activated Therapy technology to generate improved prodrug versions of FDA-approved drugs, as well as to generate prodrug versions of existing compounds that may have applications for new disease indications. Its prodrug product candidate pipeline is focused on the high need areas of attention deficit hyperactivity disorder, stimulant use disorder, and CNS rare diseases, including idiopathic hypersomnia. KemPharm's lead clinical development candidate for the treatment of stimulant use disorder, KP879, is based on its prodrug of d-methylphenidate, known as serdexmethylphnidate. In addition, the company has received FDA approval for AZSTARYS, a new once-daily treatment for attention deficit hyperactivity disorder in patents age six years and older, and for APADAZ, an immediate-release combination product containing benzhydrocodone, a prodrug of hydrocodone, and acetaminophen. KemPharm, Inc. has collaboration and license agreement, with KVK-Tech, Inc. The company was incorporated in 2006 and is headquartered in Celebration, Florida.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Clifton R. LaDuaneCFO, Secretary & TreasurerMay 27Buy9.851501,4783,275May 27 05:50 PM
Braun Samuel J10% OwnerMay 13Buy8.5510,00085,5003,070,000May 17 04:42 PM